Biomarker assay expertise

Whole exome sequencing

  • Knowing the precise mutational landscape for each patient can reveal that the drug is more efficacious in patients harboring specific mutations or sets of mutations.

  • Below $200 per sample*


    *indicative price, please consult for detailed pricing

RNA sequencing

  • RNA sequencing performed on whole tumor, on a subset of cells (cancer cells, CD8 T cells, NK cells…) can reveal that specific signalling pathways are involved in the response of patients to your drug. They can also inform/verify the effect your drugs is having on specific cell types.

  • Below $200 per sample*


    *indicative price, please consult for detailed pricing

TCR sequencing

  • Interindividual variability in the TCR repertoire (abundance and diversity of T cell clones) has been shown to influence the response to drugs. Exploring these parameters by TCR-sequencing could provide you with insights on specific responding populations as well as with the mechanism of action of your drug.

  • Below $300 per sample*


    *indicative price, please consult for detailed pricing

BCR sequencing

  • Interindividual variability in the BCR repertoire (abundance and diversity of B cell clones) has been shown to influence the response to drugs. Exploring these parameters by BCR-sequencing could provide you with insights on specific responding populations as well as with the mechanism of action of your drug.

  • Below $300 per sample*

    *indicative price, please consult for detailed pricing

Flow cytometry

  • A comprehensive characterization of the peripheral immune cells and their subsets can reveal specific immune populations involved in the response of patients to your drug. They can also inform/verify the immune response achieved by your drug .

  • Below $1500 per sample for a comprehensive characterization of the immune system (more than 150 cell types/subsets)*


    *indicative price, please consult for detailed pricing

Multiplex IHC

  • Multiplex IHC allows the spatial characterization of the tumor microenvironment (TME) by specifically assessing immune, stromal and tumor cell subsets. These have been linked to patient response to drugs and can also inform you on the effect of your drug on that TME.

  • TBD depending on the extent of the characterization you are seeking.

Multibiomarker analysis by AI/ML

  • Tumor biology is complex and a set of biomarkers usually predict with way more sensitivity and specificity which patients will respond to a drug.

    Once all the biomarker assays have been performed, Artificial intelligence/Machine learning (AI/ML) will identify the best set of biomarkers to use for patient response along with a specific scoring and cut-off for patient response. AI/ML can also identify specific patient population demographics responding to your drug.